GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Benevolent AI (GREY:BAIVF) » Definitions » Earnings Yield (Joel Greenblatt) %

Benevolent AI (Benevolent AI) Earnings Yield (Joel Greenblatt) % : -86.21% (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Benevolent AI Earnings Yield (Joel Greenblatt) %?

Benevolent AI's Enterprise Value for the quarter that ended in Dec. 2023 was $30.14 Mil. Benevolent AI's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-91.41 Mil. Benevolent AI's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2023 was -86.21%.

The historical rank and industry rank for Benevolent AI's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

BAIVF' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -4158.78   Med: -87.75   Max: 3467.51
Current: -263.16

During the past 6 years, the highest Earnings Yield (Joel Greenblatt) of Benevolent AI was 3467.51%. The lowest was -4158.78%. And the median was -87.75%.

BAIVF's Earnings Yield (Joel Greenblatt) % is ranked worse than
92.38% of 1418 companies
in the Biotechnology industry
Industry Median: -15.33 vs BAIVF: -263.16

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Benevolent AI's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2023 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Benevolent AI Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for Benevolent AI's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Benevolent AI Earnings Yield (Joel Greenblatt) % Chart

Benevolent AI Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings Yield (Joel Greenblatt) %
Get a 7-Day Free Trial - - - -63.29 -86.21

Benevolent AI Quarterly Data
Dec18 Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Earnings Yield (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only - - -63.29 - -86.21

Competitive Comparison of Benevolent AI's Earnings Yield (Joel Greenblatt) %

For the Biotechnology subindustry, Benevolent AI's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Benevolent AI's Earnings Yield (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Benevolent AI's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Benevolent AI's Earnings Yield (Joel Greenblatt) % falls into.



Benevolent AI Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

Benevolent AIs Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2023 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=-91.549/30.1406224
=-303.74 %

Benevolent AI's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-91.41 Mil.



Benevolent AI  (GREY:BAIVF) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


Benevolent AI Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Benevolent AI's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Benevolent AI (Benevolent AI) Business Description

Industry
Comparable Companies
Traded in Other Exchanges
Address
4-8 Maple Street, London, GBR, W1T 5HD
Benevolent AI is a clinical-stage AI-enabled drug discovery company. It delivers novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform powers a growing in-house pipeline of over 20 drug programmes, spanning from target discovery to clinical studies, and it maintains commercial collaborations with pharmaceutical companies.